Osaka, Japan – February 17, 2020 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approvals by the Ministry of Health, Labour and Welfare for 15 generic drugs with 31 ... Read More
Maple Grove, MN – January 28, 2020 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Clonidine Hydrochloride Extended-Release Tablets in 0.1 mg strength. Upsher-Smith’s product is AB1-rated to the branded product, KAPVAY® (clonidine ... Read More
Maple Grove, MN – January 13, 2020 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Haloperidol Tablets, USP in 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg and 20 mg strengths. ... Read More
Maple Grove, MN – January 10, 2020 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Fluvoxamine Maleate Tablets in 25 mg, 50 mg and 100 mg strengths.
The fluvoxamine tablet market had U.S. sales ... Read More
Osaka, Japan – December 12, 2019 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced the launch of two generic drugs with five strengths. They will be launched sequentially ... Read More
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be attending the 2019 Annual Meeting of the American Epilepsy Society (AES) December 6-10, 2019 in Baltimore, MD. Meeting attendees are encouraged to visit booth #526 ... Read More
Program Provides Access and Affordability for Patients Seeking Treatment for Acute Migraine
Maple Grove, MN – November 18, 2019 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has added Zembrace® SymTouch® (sumatriptan) Injection 3 mg ... Read More
Left to Right: NCPA President Bill Osborn,PharmD; Steve Moore, PharmD (winner); and Mike McBride of Upsher Smith
NCPA AWARD SPONSORED BY UPSHER-SMITH FOR ELEVENTH CONSECUTIVE YEAR
Maple Grove, MN – October 29, 2019 – Upsher-Smith Laboratories, LLC ... Read More